文献速递糖尿病

TEDDY研究中不同自身抗体级联扩散的层级顺序与1型糖尿病进展

Hierarchical Order of Distinct Autoantibody Spreading and Progression to Type 1 Diabetes in the TEDDY Study.
PubMed 文献 · Diabetes Care · 2020-07-08

TEDDY研究对具有HLA-DR-DQ遗传风险的儿童从3月龄随访至15岁,评估首个自身抗体出现后扩散至第二个自身抗体及进展为1型糖尿病的风险。608名儿童出现单一首个自身抗体,中位随访12.5年;第二个自身抗体出现类型影响1型糖尿病风险,IA-2A第二个出现风险最高,且首次血清转换年龄越小、第二个抗体出现时间越短,进展风险越高。

要点

  • 第二个自身抗体出现类型独立于首个抗体,IA-2A第二个出现进展风险最高(校正HR 16.33)。
  • 首个自身抗体为GADA或IAA对第二个抗体出现风险无显著差异(校正HR 1.12)。
  • 首次血清转换年龄越小、第二个抗体出现时间越短,1型糖尿病风险越高。

核心结论

  • 不同自身抗体扩散的层级顺序独立于首个自身抗体类型,且年龄依赖,并增加1型糖尿病进展风险。

研究设计与样本

  • TEDDY研究为前瞻性队列,纳入具有HLA-DR-DQ遗传风险的儿童,从3月龄每季度随访至15岁。
  • 608名儿童出现单一首个自身抗体(IAA n=282,GADA n=326),中位随访12.5年。
  • 自身抗体阳性定义为连续两次访视阳性并在两个实验室确认;ZnT8A在出现其他自身抗体的儿童中检测。

主要发现

  • 第二个自身抗体出现风险与首个抗体为GADA或IAA无关(校正HR 1.12;95%CI 0.88-1.42;P=0.36)。
  • 与持续单一抗体阳性儿童相比,第二个出现IAA或GADA的1型糖尿病风险校正HR为6.44(95%CI 3.78-10.98)。
  • 第二个出现IA-2A的1型糖尿病风险校正HR为16.33(95%CI 9.10-29.29;P<0.0001),第二个出现ZnT8A的校正HR为5.35(95%CI 2.61-10.95;P<0.0001)。
  • 在出现不同第二个自身抗体的儿童中,IA-2A较GADA或IAA进展为1型糖尿病的风险更高(校正HR 3.08;95%CI 2.04-4.65;P<0.0001)。
  • 首次血清转换年龄更小和第二个自身抗体出现时间更短均增加1型糖尿病风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The first-appearing β-cell autoantibody has been shown to influence risk of type 1 diabetes (T1D). Here, we assessed the risk of autoantibody spreading to the second-appearing autoantibody and further progression to clinical disease in The Environmental Determinants of Diabetes in the Young (TEDDY) study. RESEARCH DESIGN AND METHODS: Eligible children with increased HLA-DR-DQ genetic risk for T1D were followed quarterly from age 3 months up to 15 years for development of a single first-appearing autoantibody (GAD antibody [GADA], insulin autoantibody [IAA], or insulinoma antigen-2 autoantibody [IA-2A]) and subsequent development of a single second-appearing autoantibody and progression to T1D. Autoantibody positivity was defined as positivity for a specific autoantibody at two consecutive visits confirmed in two laboratories. Zinc transporter 8 autoantibody (ZnT8A) was measured in children who developed another autoantibody. RESULTS: There were 608 children who developed a single first-appearing autoantibody (IAA, n = 282, or GADA, n = 326) with a median follow-up of 12.5 years from birth. The risk of a second-appearing autoantibody was independent of GADA versus IAA as a first-appearing autoantibody (adjusted hazard ratio [HR] 1.12; 95% CI 0.88-1.42; P = 0.36). Second-appearing GADA, IAA, IA-2A, or ZnT8A conferred an increased risk of T1D compared with children who remained positive for a single autoantibody, e.g., IAA or GADA second (adjusted HR 6.44; 95% CI 3.78-10.98), IA-2A second (adjusted HR 16.33; 95% CI 9.10-29.29; P < 0.0001), or ZnT8A second (adjusted HR 5.35; 95% CI 2.61-10.95; P < 0.0001). In children who developed a distinct second autoantibody, IA-2A (adjusted HR 3.08; 95% CI 2.04-4.65; P < 0.0001) conferred a greater risk of progression to T1D as compared with GADA or IAA. Additionally, both a younger initial age at seroconversion and shorter time to the development of the second-appearing autoantibody increased the risk for T1D. CONCLUSIONS: The hierarchical order of distinct autoantibody spreading was independent of the first-appearing autoantibody type and was age-dependent and augmented the risk of progression to T1D.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Vehik K, Bonifacio E, Lernmark Å, et al. Hierarchical Order of Distinct Autoantibody Spreading and Progression to Type 1 Diabetes in the TEDDY Study. Diabetes Care. 2020. PMID: 32641373. doi:10.2337/dc19-2547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。